<p>OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC 在最近向证券交易委员会提交的文件中表示，在第二季度减少了对 KalVista Pharmaceuticals, Inc. (NASDAQ:KALV - 免费报告) 的持股比例，降幅为 53.2%。该基金在此期间出售了 90,232 股后，持有 79,460 股这家专业制药公司的股票。OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC 在最近一个季度末持有的 KalVista Pharmaceuticals 的股份价值为 898,000 美元，占其总股份的 0.16%。</p>
<p>其他几家对冲基金和机构投资者最近也买卖了 KALV 的股票。Parkman Healthcare Partners LLC 在第一季度新购入了价值约 8,698,000 美元的 KalVista Pharmaceuticals 股票。Woodline Partners LP 在第一季度将其在 KalVista Pharmaceuticals 的持股比例提高了 25.5%。Woodline Partners LP 目前持有 1,617,469 股这家专业制药公司的股票，价值为 18,666,000 美元，此前在此期间又增持了 329,068 股。Panagora Asset Management Inc. 在第二季度将其在 KalVista Pharmaceuticals 的持股比例提高了 307.0%。Panagora Asset Management Inc. 目前持有 292,593 股这家专业制药公司的股票，价值为 3,308,000 美元，此前在上个季度又增持了 220,697 股。Emerald Mutual Fund Advisers Trust 在第二季度将其在 KalVista Pharmaceuticals 的持股比例提高了 26.4%。Emerald Mutual Fund Advisers Trust 目前持有 768,972 股这家专业制药公司的股票，价值为 8,693,000 美元，此前在上个季度又增持了 160,759 股。最后，Nan Fung Trinity HK Ltd. 在第二季度新购入了价值约 1,747,000 美元的 KalVista Pharmaceuticals 股票。</p>
<h2>内部活动</h2>
<p>在其他 KalVista Pharmaceuticals 的新闻中，首席财务官 Brian Piekos 于 11 月 24 日星期一出售了 4,471 股公司的股票。该股票以平均价格 13.45 美元出售，总价值为 60,134.95 美元。出售完成后，首席财务官持有 10,529 股公司的股票，价值约为 141,615.05 美元。这笔交易代表了他们持股比例的 29.81% 的减少。该出售在与 SEC 的法律文件中披露，相关信息可通过此链接访问。此外，内部人士 Paul K. Audhya 于 11 月 24 日星期一出售了 5,296 股公司的股票。该股票以平均价格 13.45 美元出售，总价值为 71,231.20 美元。出售后，内部人士持有 131,831 股公司的股票，价值约为 1,773,126.95 美元。这代表了他们持股比例的 3.86% 的减少。该出售的 SEC 文件提供了更多信息。内部人士在过去三个月内共出售了 31,329 股公司股票，价值 437,371 美元。公司内部人士持有公司股票的 4.30%。</p>
<h2>KalVista Pharmaceuticals 股票上涨 0.2%</h2>
<p>KalVista Pharmaceuticals 股票在周五开盘价为 16.90 美元。该公司的速动比率为 7.21，流动比率为 7.22，债务与股本比率为 8.18。KalVista Pharmaceuticals, Inc. 的 12 个月低点为 7.30 美元，12 个月高点为 17.28 美元。该公司的 50 日移动平均线为 12.66 美元，200 日移动平均线为 13.14 美元。该公司的市值为 8.543 亿美元，市盈率为-4.28，贝塔值为-0.14。</p>
<p>KalVista Pharmaceuticals (NASDAQ:KALV - 获取免费报告) 最近于 11 月 10 日星期一发布了季度财报。这家专业制药公司报告本季度每股收益为（$0.92），超出分析师一致预期的（$0.96）0.04 美元。该公司在本季度的收入为 1369 万美元，而分析师预期为 603 万美元。整体来看，卖方分析师预测 KalVista Pharmaceuticals, Inc. 本财年的每股收益将为-3.56。</p>
<h2>分析师评级上调与下调</h2>
<p>KALV 最近成为多份分析师报告的主题。Citizens Jmp 在 11 月 11 日的研究报告中将 KalVista Pharmaceuticals 的目标股价从 29.00 美元下调至 28.00 美元，并对该股票给予了 “市场表现优于大盘” 的评级。花旗集团在 11 月 11 日的研究报告中重申了对 KalVista Pharmaceuticals 股票的 “市场表现优于大盘” 评级。JMP Securities 在 9 月 12 日的报告中将 KalVista Pharmaceuticals 的目标股价从 27.00 美元上调至 28.00 美元，并给予该公司 “市场表现优于大盘” 的评级。Cowen 在 12 月 3 日的研究报告中重申了对 KalVista Pharmaceuticals 股票的 “买入” 评级。最后，Weiss Ratings 在 10 月 8 日的报告中重申了对 KalVista Pharmaceuticals 股票的 “卖出（d-）” 评级。十位股票研究分析师对该股票给予了买入评级，一位分析师对该公司的股票给予了卖出评级。根据 MarketBeat 的数据，该股票的共识评级为 “适度买入”，共识目标价为 26.63 美元。</p>
<p><strong>获取我们最新的 KALV 股票报告</strong></p>
<h2>KalVista Pharmaceuticals 公司简介</h2>
<p>（免费报告）</p>
<p>KalVista Pharmaceuticals, Inc. 是一家临床阶段的制药公司，专注于发现、开发和商业化针对未满足需求疾病的药物疗法抑制剂。该公司的产品候选药物是 Sebetralstat，一种小分子血浆激肽酶抑制剂，针对遗传性血管性水肿（HAE）疾病。</p>
<h2>进一步阅读</h2>
<ul>
<li>我们更看好的五只股票比 KalVista Pharmaceuticals 更好</li>
<li>道琼斯工业平均指数（DJIA）是什么？</li>
<li>2026 年需避免的 3 只最近被下调的股票</li>
<li>3 只引领网络股票复兴的股票</li>
<li>芯片热潮回归：3 只有望获得巨大收益的股票</li>
<li>消费者非必需品股票解析</li>
<li>甲骨文股票遭重创：为何其人工智能管道可能推动 2026 年反弹</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9S0FMVg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9S0FMVg"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 1000 美元在 KalVista Pharmaceuticals 吗？</h2>
<p>在考虑 KalVista Pharmaceuticals 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 KalVista Pharmaceuticals 并不在名单上。</p>
<p>虽然 KalVista Pharmaceuticals 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

KalVista制药

<p>OCONNOR，瑞银资产管理的一个部门，在第二季度将其在 KalVista 制药的股份减少了 53.2%，目前持有价值 898,000 美元的股份。其他投资者如 Parkman Healthcare 和 Woodline Partners 则增加了他们的股份。KalVista 的股票开盘价为 16.90 美元，市值为 8.543 亿美元。分析师的评级不一，有些分析师维持 “买入” 或 “市场表现优于大盘” 的观点</p>

<p>OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC reduced its stake in shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Free Report) by 53.2% in the 2nd quarter, according to the company in its most recent filing with the Securities &amp; Exchange Commission. The fund owned 79,460 shares of the specialty pharmaceutical company's stock after selling 90,232 shares during the period. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC owned 0.16% of KalVista Pharmaceuticals worth $898,000 at the end of the most recent quarter.</p>
<div class="lb-trans"><p>OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC 在最近向证券交易委员会提交的文件中表示，在第二季度减少了对 KalVista Pharmaceuticals, Inc. (NASDAQ:KALV - 免费报告) 的持股比例，降幅为 53.2%。该基金在此期间出售了 90,232 股后，持有 79,460 股这家专业制药公司的股票。OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC 在最近一个季度末持有的 KalVista Pharmaceuticals 的股份价值为 898,000 美元，占其总股份的 0.16%。</p>
</div><p>Several other hedge funds and other institutional investors have also recently bought and sold shares of KALV. Parkman Healthcare Partners LLC acquired a new stake in shares of KalVista Pharmaceuticals in the first quarter valued at about $8,698,000. Woodline Partners LP lifted its stake in shares of KalVista Pharmaceuticals by 25.5% in the first quarter. Woodline Partners LP now owns 1,617,469 shares of the specialty pharmaceutical company's stock worth $18,666,000 after acquiring an additional 329,068 shares during the period. Panagora Asset Management Inc. boosted its holdings in KalVista Pharmaceuticals by 307.0% in the second quarter. Panagora Asset Management Inc. now owns 292,593 shares of the specialty pharmaceutical company's stock valued at $3,308,000 after acquiring an additional 220,697 shares during the last quarter. Emerald Mutual Fund Advisers Trust boosted its holdings in KalVista Pharmaceuticals by 26.4% in the second quarter. Emerald Mutual Fund Advisers Trust now owns 768,972 shares of the specialty pharmaceutical company's stock valued at $8,693,000 after acquiring an additional 160,759 shares during the last quarter. Finally, Nan Fung Trinity HK Ltd. acquired a new stake in KalVista Pharmaceuticals during the 2nd quarter valued at approximately $1,747,000.</p>
<div class="lb-trans"><p>其他几家对冲基金和机构投资者最近也买卖了 KALV 的股票。Parkman Healthcare Partners LLC 在第一季度新购入了价值约 8,698,000 美元的 KalVista Pharmaceuticals 股票。Woodline Partners LP 在第一季度将其在 KalVista Pharmaceuticals 的持股比例提高了 25.5%。Woodline Partners LP 目前持有 1,617,469 股这家专业制药公司的股票，价值为 18,666,000 美元，此前在此期间又增持了 329,068 股。Panagora Asset Management Inc. 在第二季度将其在 KalVista Pharmaceuticals 的持股比例提高了 307.0%。Panagora Asset Management Inc. 目前持有 292,593 股这家专业制药公司的股票，价值为 3,308,000 美元，此前在上个季度又增持了 220,697 股。Emerald Mutual Fund Advisers Trust 在第二季度将其在 KalVista Pharmaceuticals 的持股比例提高了 26.4%。Emerald Mutual Fund Advisers Trust 目前持有 768,972 股这家专业制药公司的股票，价值为 8,693,000 美元，此前在上个季度又增持了 160,759 股。最后，Nan Fung Trinity HK Ltd. 在第二季度新购入了价值约 1,747,000 美元的 KalVista Pharmaceuticals 股票。</p>
</div><h2>Insider Activity</h2>
<div class="lb-trans"><h2>内部活动</h2>
</div><p>In other KalVista Pharmaceuticals news, CFO Brian Piekos sold 4,471 shares of the firm's stock in a transaction that occurred on Monday, November 24th. The stock was sold at an average price of $13.45, for a total value of $60,134.95. Following the completion of the sale, the chief financial officer owned 10,529 shares of the company's stock, valued at approximately $141,615.05. This trade represents a 29.81% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider Paul K. Audhya sold 5,296 shares of the business's stock in a transaction that occurred on Monday, November 24th. The shares were sold at an average price of $13.45, for a total value of $71,231.20. Following the sale, the insider owned 131,831 shares of the company's stock, valued at approximately $1,773,126.95. This represents a 3.86% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 31,329 shares of company stock worth $437,371 in the last three months. Company insiders own 4.30% of the company's stock.</p>
<div class="lb-trans"><p>在其他 KalVista Pharmaceuticals 的新闻中，首席财务官 Brian Piekos 于 11 月 24 日星期一出售了 4,471 股公司的股票。该股票以平均价格 13.45 美元出售，总价值为 60,134.95 美元。出售完成后，首席财务官持有 10,529 股公司的股票，价值约为 141,615.05 美元。这笔交易代表了他们持股比例的 29.81% 的减少。该出售在与 SEC 的法律文件中披露，相关信息可通过此链接访问。此外，内部人士 Paul K. Audhya 于 11 月 24 日星期一出售了 5,296 股公司的股票。该股票以平均价格 13.45 美元出售，总价值为 71,231.20 美元。出售后，内部人士持有 131,831 股公司的股票，价值约为 1,773,126.95 美元。这代表了他们持股比例的 3.86% 的减少。该出售的 SEC 文件提供了更多信息。内部人士在过去三个月内共出售了 31,329 股公司股票，价值 437,371 美元。公司内部人士持有公司股票的 4.30%。</p>
</div><h2>KalVista Pharmaceuticals Stock Up 0.2%</h2>
<div class="lb-trans"><h2>KalVista Pharmaceuticals 股票上涨 0.2%</h2>
</div><p>KalVista Pharmaceuticals stock opened at $16.90 on Friday. The company has a quick ratio of 7.21, a current ratio of 7.22 and a debt-to-equity ratio of 8.18. KalVista Pharmaceuticals, Inc. has a 12-month low of $7.30 and a 12-month high of $17.28. The firm's fifty day moving average is $12.66 and its 200 day moving average is $13.14. The company has a market capitalization of $854.30 million, a PE ratio of -4.28 and a beta of -0.14.</p>
<div class="lb-trans"><p>KalVista Pharmaceuticals 股票在周五开盘价为 16.90 美元。该公司的速动比率为 7.21，流动比率为 7.22，债务与股本比率为 8.18。KalVista Pharmaceuticals, Inc. 的 12 个月低点为 7.30 美元，12 个月高点为 17.28 美元。该公司的 50 日移动平均线为 12.66 美元，200 日移动平均线为 13.14 美元。该公司的市值为 8.543 亿美元，市盈率为-4.28，贝塔值为-0.14。</p>
</div><p>KalVista Pharmaceuticals (NASDAQ:KALV - Get Free Report) last posted its quarterly earnings results on Monday, November 10th. The specialty pharmaceutical company reported ($0.92) EPS for the quarter, topping analysts' consensus estimates of ($0.96) by $0.04. The company had revenue of $13.69 million during the quarter, compared to analyst estimates of $6.03 million. As a group, sell-side analysts predict that KalVista Pharmaceuticals, Inc. will post -3.56 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>KalVista Pharmaceuticals (NASDAQ:KALV - 获取免费报告) 最近于 11 月 10 日星期一发布了季度财报。这家专业制药公司报告本季度每股收益为（$0.92），超出分析师一致预期的（$0.96）0.04 美元。该公司在本季度的收入为 1369 万美元，而分析师预期为 603 万美元。整体来看，卖方分析师预测 KalVista Pharmaceuticals, Inc. 本财年的每股收益将为-3.56。</p>
</div><h2>Analyst Upgrades and Downgrades</h2>
<div class="lb-trans"><h2>分析师评级上调与下调</h2>
</div><p>KALV has been the topic of a number of recent analyst reports. Citizens Jmp dropped their price target on shares of KalVista Pharmaceuticals from $29.00 to $28.00 and set a &#34;market outperform&#34; rating on the stock in a research report on Tuesday, November 11th. Citigroup reissued a &#34;market outperform&#34; rating on shares of KalVista Pharmaceuticals in a research note on Tuesday, November 11th. JMP Securities boosted their target price on shares of KalVista Pharmaceuticals from $27.00 to $28.00 and gave the company a &#34;market outperform&#34; rating in a report on Friday, September 12th. Cowen reaffirmed a &#34;buy&#34; rating on shares of KalVista Pharmaceuticals in a research report on Wednesday, December 3rd. Finally, Weiss Ratings reiterated a &#34;sell (d-)&#34; rating on shares of KalVista Pharmaceuticals in a report on Wednesday, October 8th. Ten equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat, the stock has a consensus rating of &#34;Moderate Buy&#34; and a consensus price target of $26.63.</p>
<div class="lb-trans"><p>KALV 最近成为多份分析师报告的主题。Citizens Jmp 在 11 月 11 日的研究报告中将 KalVista Pharmaceuticals 的目标股价从 29.00 美元下调至 28.00 美元，并对该股票给予了 “市场表现优于大盘” 的评级。花旗集团在 11 月 11 日的研究报告中重申了对 KalVista Pharmaceuticals 股票的 “市场表现优于大盘” 评级。JMP Securities 在 9 月 12 日的报告中将 KalVista Pharmaceuticals 的目标股价从 27.00 美元上调至 28.00 美元，并给予该公司 “市场表现优于大盘” 的评级。Cowen 在 12 月 3 日的研究报告中重申了对 KalVista Pharmaceuticals 股票的 “买入” 评级。最后，Weiss Ratings 在 10 月 8 日的报告中重申了对 KalVista Pharmaceuticals 股票的 “卖出（d-）” 评级。十位股票研究分析师对该股票给予了买入评级，一位分析师对该公司的股票给予了卖出评级。根据 MarketBeat 的数据，该股票的共识评级为 “适度买入”，共识目标价为 26.63 美元。</p>
</div><p><strong>Get Our Latest Stock Report on KALV</strong></p>
<div class="lb-trans"><p><strong>获取我们最新的 KALV 股票报告</strong></p>
</div><h2>KalVista Pharmaceuticals Company Profile</h2>
<div class="lb-trans"><h2>KalVista Pharmaceuticals 公司简介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company's product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).</p>
<div class="lb-trans"><p>KalVista Pharmaceuticals, Inc. 是一家临床阶段的制药公司，专注于发现、开发和商业化针对未满足需求疾病的药物疗法抑制剂。该公司的产品候选药物是 Sebetralstat，一种小分子血浆激肽酶抑制剂，针对遗传性血管性水肿（HAE）疾病。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>进一步阅读</h2>
</div><ul>
<li>Five stocks we like better than KalVista Pharmaceuticals</li>
<li>What is the Dow Jones Industrial Average (DJIA)?</li>
<li>3 Recently Downgraded Stocks to Avoid in 2026</li>
<li>3 Tickers Leading a Meme Stock Revival</li>
<li>The Chip Boom Is Back: 3 Stocks Positioned for Huge Gains</li>
<li>Consumer Discretionary Stocks Explained</li>
<li>Oracle Stock Hit Hard: Why Its AI Pipeline Could Drive a 2026 Rally</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票比 KalVista Pharmaceuticals 更好</li>
<li>道琼斯工业平均指数（DJIA）是什么？</li>
<li>2026 年需避免的 3 只最近被下调的股票</li>
<li>3 只引领网络股票复兴的股票</li>
<li>芯片热潮回归：3 只有望获得巨大收益的股票</li>
<li>消费者非必需品股票解析</li>
<li>甲骨文股票遭重创：为何其人工智能管道可能推动 2026 年反弹</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9S0FMVg" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=KALV"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in KalVista Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1000 美元在 KalVista Pharmaceuticals 吗？</h2>
</div><p>Before you consider KalVista Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 KalVista Pharmaceuticals 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and KalVista Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 KalVista Pharmaceuticals 并不在名单上。</p>
</div><p>While KalVista Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 KalVista Pharmaceuticals 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

OCONNOR 是瑞银资产管理美洲有限责任公司的一家独立业务部门，持有 KalVista 制药公司价值 898,000 美元的股份